J Cancer 2019; 10(25):6374-6383. doi:10.7150/jca.30139 This issue Cite

Research Paper

CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients

Li-Ming Tan1,2,6, Xi Li1,3,4, Cheng-Feng Qiu2, Tao Zhu1,3,4, Cheng-Ping Hu5, Ji-Ye Yin1,3,4, Wei Zhang1,3,4, Hong-Hao Zhou1,3,4, Zhao-Qian Liu1,3,4✉

1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P. R. China;
2. Department of Evidence-based Medicine and Clinical Center, The First People's Hospital of Huaihua City,Huaihua 418000, P. R China;
3. Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China;
4. National Clinical Research Center for Geriatric Disorders, Changsha 410008, P.R. China;
5. Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P. R. China;
6. Department of Clinical Pharmacy, The Second People's Hospital of Huaihua City, Huaihua 418000, P. R China.

Citation:
Tan LM, Li X, Qiu CF, Zhu T, Hu CP, Yin JY, Zhang W, Zhou HH, Liu ZQ. CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. J Cancer 2019; 10(25):6374-6383. doi:10.7150/jca.30139. https://www.jcancer.org/v10p6374.htm
Other styles

File import instruction

Abstract

Cisplatin-based chemotherapy is the foundation of treatment for major non-small cell lung cancer (NSCLC) patients. However, cisplatin resistance is still a challenging issue, and the molecular mechanisms underlying this resistance remain to be fully explored. CLEC4M, a Ca2+-dependent C-type lectin, has recently been found to correlate with tumourigenesis. This study mainly focused on whether CLEC4M impacts clinical prognosis and how CLEC4M contributes to cisplatin resistance in NSCLC. Our results found that CLEC4M was correlated with poor prognosis in patients with lung cancer. In addition, a positive association between CLEC4M expression and the IC50 values of cisplatin was found, which suggests that CLEC4M may impact cisplatin sensitivity. In vitro results from cultured A549 and H1299 cells confirmed that CLEC4M could enhance cisplatin resistance, while CLEC4M knockdown led to higher sensitivity to cisplatin in these cells. Further experiments showed that the underlying mechanisms included inhibition of cisplatin-induced cell apoptosis by CLEC4M and improved DNA repair capacity by upregulating XPA and ERCC1 expression. In addition, CLEC4M was able to promote cell migration with or without cisplatin treatment. Collectively, these findings suggest the potential clinical significance of CLEC4M inhibition in overcoming cisplatin resistance in NSCLC patients.

Keywords: CLEC4M, non-small cell lung cancer, cisplatin resistance


Citation styles

APA
Tan, L.M., Li, X., Qiu, C.F., Zhu, T., Hu, C.P., Yin, J.Y., Zhang, W., Zhou, H.H., Liu, Z.Q. (2019). CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. Journal of Cancer, 10(25), 6374-6383. https://doi.org/10.7150/jca.30139.

ACS
Tan, L.M.; Li, X.; Qiu, C.F.; Zhu, T.; Hu, C.P.; Yin, J.Y.; Zhang, W.; Zhou, H.H.; Liu, Z.Q. CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. J. Cancer 2019, 10 (25), 6374-6383. DOI: 10.7150/jca.30139.

NLM
Tan LM, Li X, Qiu CF, Zhu T, Hu CP, Yin JY, Zhang W, Zhou HH, Liu ZQ. CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. J Cancer 2019; 10(25):6374-6383. doi:10.7150/jca.30139. https://www.jcancer.org/v10p6374.htm

CSE
Tan LM, Li X, Qiu CF, Zhu T, Hu CP, Yin JY, Zhang W, Zhou HH, Liu ZQ. 2019. CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. J Cancer. 10(25):6374-6383.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image